KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) EBITDA (2016 - 2025)

Historic EBITDA for Exact Sciences (EXAS) over the last 17 years, with Q4 2025 value amounting to -$82.6 million.

  • Exact Sciences' EBITDA rose 9057.51% to -$82.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$206.3 million, marking a year-over-year increase of 8032.83%. This contributed to the annual value of -$206.3 million for FY2025, which is 8032.83% up from last year.
  • Exact Sciences' EBITDA amounted to -$82.6 million in Q4 2025, which was up 9057.51% from -$25.5 million recorded in Q3 2025.
  • Exact Sciences' EBITDA's 5-year high stood at $6.8 million during Q3 2023, with a 5-year trough of -$876.4 million in Q4 2024.
  • In the last 5 years, Exact Sciences' EBITDA had a median value of -$101.4 million in 2024 and averaged -$146.0 million.
  • As far as peak fluctuations go, Exact Sciences' EBITDA skyrocketed by 10496.1% in 2023, and later tumbled by 119177.19% in 2024.
  • Over the past 5 years, Exact Sciences' EBITDA (Quarter) stood at -$221.4 million in 2021, then skyrocketed by 46.32% to -$118.9 million in 2022, then soared by 42.93% to -$67.8 million in 2023, then tumbled by 1191.77% to -$876.4 million in 2024, then surged by 90.58% to -$82.6 million in 2025.
  • Its EBITDA stands at -$82.6 million for Q4 2025, versus -$25.5 million for Q3 2025 and -$2.1 million for Q2 2025.